Phase 3 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Healthy babies who are between 6 and 8 weeks old (both ages included)
- Babies who weigh at least 3.2 kg (about 7 pounds)
- Babies who were born after a full-term pregnancy (at least 37 weeks)
- A parent or legal guardian has signed the consent forms to allow the baby to take part
Who may not be able to join:
- Babies who have previously had any of these diseases: Hib (a type of bacterial infection), Hepatitis B, diphtheria, tetanus, whooping cough (pertussis), or polio
- Babies who have been in close contact with someone confirmed to have Hib, Hepatitis B, diphtheria, whooping cough, tetanus, or polio in the 30 days before registering for the study
- Babies who have previously had a COVID-19 (SARS-CoV-2) infection
- Babies whose mother tests positive for Hepatitis B antigen or HIV
- Babies who have had a fever of 38.0°C (100.4°F) or higher within the 3 days before enrolling
- Babies who have received certain other vaccines in the 30 days before enrolling — vaccines for pneumococcal disease, rotavirus, Hepatitis B, and BCG (a tuberculosis vaccine) are exceptions to this rule (confirm with trial site)
- Babies who have previously received any vaccines for diphtheria, tetanus, whooping cough, Hib, or polio — either alone or in combination
- Babies who have received medications that suppress or alter the immune system
- Babies who have previously received blood or blood-derived products
- Babies with a known allergy or hypersensitivity to any ingredient in the study vaccines
- Babies who are already participating in another interventional clinical trial within 4 weeks of the expected first vaccination in this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-6987-4156
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Seroprotection/seroconversion rate; Geometric mean concentration (GMC) for pertussis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.